DDInter1033 DDInter1676
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Leflunomide {u} (Compound) resembles {v} (Compound) Niflumic Acid
Leflunomide {u} (Compound) treats {v} (Disease) systemic scleroderma
Leflunomide {u} (Compound) binds {v} (Gene) PTK2B
Leflunomide {u} (Compound) upregulates {v} (Gene) WIF1
Leflunomide {u} (Compound) downregulates {v} (Gene) MRPS16
Leflunomide {u} (Compound) causes {v} (Side Effect) Skin nodule
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Losartan
Leflunomide (Compound) resembles Niflumic Acid (Compound)
Leflunomide (Compound) treats systemic scleroderma (Disease)
Leflunomide (Compound) binds PTK2B (Gene)
Leflunomide (Compound) upregulates WIF1 (Gene)
Leflunomide (Compound) downregulates MRPS16 (Gene)
Leflunomide (Compound) causes Skin nodule (Side Effect)
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Losartan